- ticket title
- Shanghai Electric Showcases Smart Energy Solution at China International Industrial Expo on World’s Clean Up Day
- Huawei FusionServer Pro 2488H V5 Sets a New Record in SAP® BWH Benchmark
- Secureworks Named a Leader in the IDC MarketScape: Worldwide Managed Security Services (MSS) 2020 Vendor Assessment
- Secureworks تحصد لقب رائدة في عالم IDC MarketScape: تقييم البائعين لعام 2020 الخاص بخدمات الأمن المُدارة في كل أنحاء العالم (MSS)
- جريت وول موتورز تعلن خطة الطرح العالمية لعربات نصف نقل من الفئة P
– New Beijing Office Expands Services in Asia Pacific Region
BEIJING, Oct. 2, 2012 /PRNewswire – QPS Holdings, LLC, a leading full-service Clinical Research Organization, today announced the launch of its QPS Qualitix China Office, built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China. The move into China continues QPS’ expansion into the Asia Pacific region and builds upon its existing presence in Taiwan and India.
Capitalizing on its experience conducting clinical trials through partners in China, the QPS Qualitix China Office will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China. The expansion into China continues QPS’ development of its worldwide capabilities and focus on emerging markets.
The QPS Qualitix China Office will provide a full range of knowledge-based contract research services, including comprehensive clinical trial management and regulatory submission preparation. The new China Office will tap QPS’ global resources and expertise to develop customized offerings in key therapeutic areas, along with phase II-IV studies, biostatistics, data management, medical writing, vaccines, medical devices and diagnostics.
“The QPS Qualitix China Office will leverage QPS’ quality and training systems to offer customized, high-quality drug development solutions best suited for local Chinese biopharma, as well as global biopharma’s local affiliates,” says Vincent Yen, general manager of QPS Qualitix China. “We have an aggressive growth plan for China and anticipate increasing QPS’ total staff there during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world’s most dynamic marketplaces.”
The new QPS Qualitix China Office is located in the Chao Yang District, near the World Trade Center of Beijing. The office will be headed by David Hsu, who brings years of experience in the clinical research industry, with both global pharmaceutical companies and CROs.
QPS Qualitix is one of Asia’s leading providers of biopharmaceutical services and has had a presence in the Asia/Pacific region for over nine years. With more than 280 employees operating from two regional offices in Asia, QPS Qualitix is the partner of choice for both global and local biopharmaceutical companies to conduct drug development in China.
QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and clinical drug development. We provide quality services in CNS Pharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early Stage & Phase II – IV Clinical Research to clients worldwide. Our regional facilities and offices are located in the USA, China, Taiwan, India, Netherlands, Austria, Czech Republic, Croatia, Slovenia, Serbia, Bosnia, Hungary, Spain, Germany and the United Kingdom. Business development offices are maintained throughout the US, Europe, and Asia. For more information, please visit www.qps.com.